RxDoctor Payments Data

Erol Kosar, MD

Clinical Cardiac Electrophysiology · Torrance, CANPI 1104820927

Payments from drug & device makers

$98,827in general payments, 2019–2025

Across 508 payments — averaging $194.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$63K
  • Boston Scientific$13K
  • Impulse Dynamics (USA) Inc.$8K
  • Abbott$7K
  • Biotronik Inc.$2K
  • Medical Device Business Services, Inc.$736
  • plus $5K from 27 others

What the payments were for

  • Consulting fees$8003%
  • Speaking & faculty fees$8,25035%
  • Travel & lodging$4,05317%
  • Food & beverage$10,23343%
  • Education$4502%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,827 in reported general payments places this provider in the 70th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$433,052
Medicare patients
1,720
Services billed
8,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban851$1,040,883
XareltoRivaroxaban254$294,287
VyndamaxTafamidis12$262,116
EntrestoSacubitril/Valsartan137$167,923
JardianceEmpagliflozin50$68,378
MultaqDronedarone Hcl11$14,832
Repatha SureclickEvolocumab22$14,755
Metoprolol Succinate504$7,411
SotalolSotalol Hcl316$6,780
Diltiazem 24hr Er (Cd)Diltiazem Hcl88$3,062
Atorvastatin Calcium315$2,988
Diltiazem 24hr Er (La)Diltiazem Hcl32$2,901
Diltiazem 24hr ErDiltiazem Hcl54$2,482
Losartan Potassium190$2,080
Amiodarone Hcl143$2,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$655$1,302,999863 claims
Johnson & JohnsonXarelto$496$294,287254 claims
NovartisEntresto$681$167,923137 claims
Boehringer IngelheimJardiance$61$68,37850 claims
Sanofi-aventis U.S. LLCMultaq$209$14,83211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →